Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

89.65 +1.81 (+2.06%)
Streaming Delayed Price Updated: 1:47 PM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 87,397
Open 88.79
Bid (Size) 89.52 (100)
Ask (Size) 89.81 (100)
Prev. Close 87.84
Today's Range 87.84 - 90.78
52wk Range 58.71 - 122.20
Shares Outstanding 66,684,077
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-14.6%
-14.6%
1 Month
+5.2%
+5.2%
3 Month
-7.0%
-7.0%
6 Month
-15.9%
-15.9%
1 Year
+51.5%
+51.5%

More News

Read More
News headline image
My Top 3 Stocks to Buy in May ↗
Via The Motley Fool
Topics Earnings
News headline image
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results ↗
Via Benzinga
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Surpasses Q1 Estimates as U.S. Hypothalamic Obesity Launch Accelerates ↗
Via Chartmill
Rhythm Pharmaceuticals (NASDAQ:RYTM) Posts Q4 Revenue Beat and Narrows Loss ↗
Via Chartmill
News headline image
Rhythm (RYTM) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday ↗
Via The Motley Fool
News headline image
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
Via MarketMinute
News headline image
Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
Via Finterra
Topics Economy Intellectual Property
News headline image
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
Via MarketMinute
Topics Intellectual Property
News headline image
Rhythm Pharmaceuticals Announces Changes to Board of Directors
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Is This Weight Loss Drug Stock a Buy After a New Approval? ↗
Via The Motley Fool
News headline image
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharma (RYTM) Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings

Frequently Asked Questions

Is Rhythm Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Rhythm Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Rhythm Pharmaceuticals, Inc. - Common Stock trade on?
Rhythm Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock is RYTM on the Nasdaq Stock Market
What is the current price of Rhythm Pharmaceuticals, Inc. - Common Stock?
The current price of Rhythm Pharmaceuticals, Inc. - Common Stock is 89.65
When was Rhythm Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Rhythm Pharmaceuticals, Inc. - Common Stock was at 05/26/26 01:47 PM ET
What is the market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock is 5.98B
How many shares of Rhythm Pharmaceuticals, Inc. - Common Stock are outstanding?
Rhythm Pharmaceuticals, Inc. - Common Stock has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.